Product News
Filter News
Found 178,661 articles
-
A Los Angeles jury sided with 68-year-old Joanne Anderson, who was diagnosed with mesothelioma allegedly linked to a Johnson & Johnson talc product. It is the second similar award regarding the product.
-
Myomo Announces MyoPro Availability in 16 New U.S. Locations
5/24/2018
Includes Efforts in Jacksonville, Florida, and Scottsdale, Arizona, to Serve Patients from Nationally Acclaimed Health Systems
-
AGC Biologics Cleared for Commercial Manufacture of Portola's FDA-Approved Andexxa®
5/24/2018
Drug Substance produced in AGC Biologics' facility in Bothell, Washington
-
Spinal Elements® Announces Expanded Commercial Release of its Clutch® Interspinous Process Device
5/24/2018
Spinal Elements, a spine technology company, today announced the release of its Clutch interspinous process device.
-
Calidi Biotherapeutics, Inc. announces its corporate vision in groundbreaking cancer drug development and appoints Allan Camaisa as CEO
5/24/2018
Calidi Biotherapeutics is developing a novel cell-based platform for delivery of oncolytic viruses, which can be used standalone, or in combination with other immunotherapies.
-
EndoClot Expands GI Hemostasis Portfolio With Launch of EndoClot® Adhesive
5/24/2018
EndoClot Plus, Inc., a privately held medical device company founded by surgeons and biomaterial scientists announces the CE approval of EndoClot® Adhesive manufactured by EndoClot Plus Co., Ltd. located in Suzhou, China.
-
New Real-World Study Finds Long-Term XARELTO® (rivaroxaban) Use Resulted in Fewer Strokes and Systemic Emboli Compared to Warfarin in Frail Patients with Non-Valvular Atrial Fibrillation
5/24/2018
The Janssen Pharmaceutical Companiesof Johnson & Johnson today announced new real-world data that showed frail patients with non-valvular atrial fibrillation (NVAF) experienced significantly fewer strokes and systemic emboli when treated with XARELTO® (rivaroxaban) over a two-year period compared to those taking warfarin.
-
Best Particle Therapy, Inc. is Developing a Highly Revolutionary New Treatment for Cancer Therapy
5/24/2018
The most precise and conformal Cancer Therapy, using hypo-fractionation, supported by a range of the most advanced cyclotrons for research and radioisotope production for medical diagnosis and therapy in the world
-
For investors looking for a big pharma stock, AbbVie and Pfizer are both top choices.
-
HETLIOZ® (tasimelteon) Effective in Treating Jet Lag during Transatlantic Travel
5/23/2018
HETLIOZ® demonstrates significant improvement in objective and subjective measures of Jet Lag during 5 hour and 8 hour time zone transatlantic travel from the US to the UK
-
Veracyte Announces New Study Published in JAMA Surgery Demonstrates Afirma GSC’s Ability to Significantly Reduce Unnecessary Surgeries in Thyroid Cancer Diagnosis
5/23/2018
Veracyte, Inc. announced that clinical validation data published for the first time today – in JAMA Surgery – demonstrate that the next-generation Afirma Genomic Sequencing Classifier (GSC) identifies at least one third more benign thyroid nodules among those deemed indeterminate by cytopathology, as compared to the original, market-leading Afirma test.
-
Newest Generation of Leading Heart Stent is Now Approved in the U.S. for People with Coronary Artery Disease
5/23/2018
Abbott (NYSE: ABT) today announced it received approval from the U.S. Food and Drug Administration (FDA) for XIENCE SierraTM, the newest generation of the company's gold-standard XIENCE everolimus-eluting coronary stent system.
-
Simulations Plus Releases GastroPlus™ Version 9.6
5/23/2018
Simulations Plus, Inc. (NASDAQ: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, and chemicals industries, today announced that it has released version 9.6 of its flagship PBPK modeling program, GastroPlus™.
-
IOTA Pharmaceuticals Announce the Creation of a Glioblastoma Drug Bank to Support and Accelerate New Research Into Brain Cancer Therapy
5/23/2018
IOTA Pharmaceuticals Ltd today announced the creation of a new resource, the Glioblastoma (GBM) Drug Bank, to accelerate drug discovery research in brain cancer, especially glioblastoma.
-
Otsuka and Lundbeck to Start Third Phase 3 Trial in June to Evaluate Brexpiprazole in the Treatment of Agitation in Patients with Alzheimer's Disease
5/23/2018
Otsuka Pharmaceutical Company, Ltd. (Otsuka) and Lundbeck announce that the two companies’ third clinical Phase 3 study of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type will commence in June.
-
Fujifilm Announces The Expansion Of Its Fill Finish Services To Include Late Phase And Commercial Production Of Gene Therapies And Viral Vaccines To Become An End To End Solutions Provider
5/23/2018
FUJIFILM Diosynth Biotechnologies(Fujifilm), has announced the extension of its gene therapy and viral vaccine Fill/Finish.
-
Kraig Biocraft Laboratories Develops New Breakthrough Spider Silk DNA Synthesis Protocols Accelerating Time to Market for New Products
5/23/2018
Kraig Labs’ R&D team raises the bar in transgenic research.
-
ProterixBio Presents Results from Multiple COPD Clinical Studies at the American Thoracic Society International Conference
5/23/2018
ProterixBio, Inc. today announced that results from three clinical studies of subjects with chronic obstructive pulmonary disease (COPD).
-
Presentation of New Data on MDxHealth’s Prostate and Bladder Cancer Products at AUA 2018 Annual Meeting
5/23/2018
MDxHealth SA announces that significant data on the performance of its SelectMDx, and ConfirmMDx tests for prostate cancer and AssureMDx test for bladder cancer were presented in two moderated posters and one podium presentation at the American Urological (AUA) Annual Meeting 18-21 May in San Francisco.
-
Apogenix Provides Update on Clinical Development of Asunercept
5/23/2018
Apogenix AG provides an update on the clinical development and approval strategy of its lead drug candidate asunercept.